#Ifactor health free#

#Ifactor health free#

i-FACTOR is free of many safety risks seen with other products such as ectopic bone formation and on average costs at least 30% less expensive than other drug-device combination products. One of only two Class III FDA-PMA approved spinal bone grafts, i-FACTOR is the leading evidence-based alternative and is powered by a first of its kind molecule called P-15: Osteogenic Cell Binding Peptide. In this study i-FACTOR demonstrated high fusion rates and statistical superiority vs. See more >Ĭerapedics is an advanced orthobiologics company, enhancing the science of bone repair in orthopedic and spinal fusion procedures with i-FACTOR® Peptide Enhanced Bone Graft.Īmong 400+ spinal bone grafts on the market, spine surgeons can feel confident in choosing i-FACTOR Peptide Enhanced Bone Graft which is backed by Level 1 human clinical data from an IDE study published in Spine and Neurosurgery. Partnered with senior leadership to design organization & successfully implement talent acquisition, onboarding, training, & long-term staffing.

Led HR strategy & tactics for Elanco’s entry into the Companion Animal Health business.

Integral role in the transformation of HR model to HRBPs & COEs.

Designed new roles, positions, organizations, job/compensation structures, competency models, & career paths.

Strategized with senior leadership to design & implement robust & customized variable compensation programs To prevent space travelers from arriving at their destinations completely insane, the passengers must be drugged insensible to avoid making memories of the.

HR lead role in the redesign of external workforce (over 1000 personnel) for utilization & cost efficiencies ($10M savings).

Led HR strategy & tactics for acquisition restructuring, organization design, & staffing rationalization for the global G&A functions & U.S./Canada commercial business as part of Lilly’s $5.4B acquisition of Swiss-based Novartis Animal Health.

Led complex organizational change for Boulder Brands integration into Pinnacle Foods in 1st year post-acquisition.

Recognized for aligning HR strategy with talent while ensuring that the required structure, capabilities, culture, & leadership are developed & in place to achieve business objectives. Have successfully managed human capital & led HR teams in Fortune 150, mid-size, & entrepreneurial organizations across varied industries including medical device, pharmaceutical, CPG/food, healthcare, animal health, & higher education. Recently, a second Level 1 investigational device exemption (IDE) study was initiated for use in transforaminal lumbar interbody fusion.Senior level Human Resources leader with over 20 years of progressive HR experience. i-FACTOR is also supported by three additional published peer-reviewed clinical studies from international usage. These results were used to support FDA approval of i-FACTOR in this indication.

For example, study results published in the peer-reviewed journal Spine involving 319 patients who underwent anterior cervical discectomy and fusion surgery showed that i-FACTOR was superior to autograft in composite overall success one-year post-surgery. How does this product benefit the surgical team and aid in better outcomes?Ĭompleted clinical research indicates that i-FACTOR is statistically superior to autograft in overall patient success. While these products are commonly used by surgeons, the P-15 technology is supported by Level 1 human clinical data and has the potential to offer a safe, effective and economical alternative that surgeons need and that aligns with the values of healthcare systems.

Other alternatives include bone morphogenetic proteins (BMPs), demineralized bone matrix (DBM), and stem cell therapies.

This approach presents risks such as infection, nerve damage, bleeding, and chronic pain around the graft site. Historically, the gold standard was using a bone graft obtained from the patient’s pelvis to promote fusion (autograft). What sets this product apart from others available in the industry?